Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

Cabozantinib is an inhibitor of multiple receptor tyrosine kinases, including MET and VEGFR2. In a phase II clinical trial in advanced prostate cancer (PCa), cabozantinib treatment improved bone scans in 68% of evaluable patients. Our studies aimed to determine the expression of cabozantinib targets...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Nguyen, Holly M., Ruppender, Nazanin, Zhang, Xiaotun, Brown, Lisha G., Gross, Ted S., Morrissey, Colm, Gulati, Roman, Vessella, Robert L., Schimmoller, Frauke, Aftab, Dana T., Corey, Eva
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2013
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3808282/
https://ncbi.nlm.nih.gov/pubmed/24205338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0078881
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items